Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Graminaceae allergenic extract is a standardized biologic allergen extract derived from grass pollen, developed by Lofarma S.p.A. for the diagnosis and treatment of respiratory allergies, including allergic rhinitis and allergic asthma. It acts as an immunomodulator by targeting the IgE-mediated allergic response pathway, aiming to induce desensitization and clinical tolerance in patients sensitized to grass pollens. The extract is utilized in both diagnostic skin prick testing and allergen immunotherapy (AIT). Clinical development has included Phase 2 biological standardization studies to define its potency in histamine equivalent prick (HEP) units and establish reference preparations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on graminaceae allergenic extract.